Abstract
The objective was to evaluate the association between antiretroviral therapy and AIDS mortality in New York City (NYC). Design was a population-based case-control study. We randomly selected 150 case patients and 150 control patients whose AIDS diagnosis was made during 1994 to 1996 (male: female, 2:1) from among 19,238 persons reported to the NYC Health Department HIV/AIDS Reporting System (HARS). Case patients had died of AIDS-related causes in 1996. Control patients, category matched with case patients on gender, were not known to have died by the end of 1996. Analysis was performed on 279 patients (142 cases and 137 controls). Cases and controls were similar in age, gender, race, HIV transmission category, and health insurance coverage. The median baseline CD4 count was 30 cells/μL for those who died and 103 cells/μL for survivors (p<0.001). The prescription of HAART (antiretroviral combination that includes at least one protease inhibitor) in 1996 was strongly associated with survival in univariate analysis (OR=5.1, 95%CI=2.5-10.2). This association remained in a logistic regression analysis after adjusting for sex, age, race, health insurance status, HIV transmission categories, year of AIDS diagnosis, baseline CD4 count, and other antiretroviral therapy (AOR=8.6, 95%CI=3.5-20.7). Prescription of combination therapy other than HAART in 1996 and baseline CD4 count were also associated with survival, but less strongly so. The survival benefit of HAART extends beyond the confines of a few highly selected patients into the “real world,” reducing AIDS deaths at the population level. This population-based study supports the likelihood that the introduction of HAART in 1996 played a primary role in the decline in NYC AIDS mortality.
Key words: Antiretroviral Therapy, HAART, Mortality, Protease Inhibitors
Full Text
The Full Text of this article is available as a PDF (446.4 KB).
Footnotes
At the time of the study, Drs. Wong and Chiasson and Ms. Heffess were affiliated with Columbia University and the New York City Department of Health; Drs. Reggy and Simonds were affiliated with the Centers for Disease Control and Prevention, Atlanta, Georgia; and Ms. Loo was affiliated with the New York City Department of Health.
Dr. Chiasson is currently with Medical and Health Research Association of NYC, Incorporated; Ms. Loo is currently with the California Department of Health Services—STD Control Branch.
References
- 1.HIV/AIDS Surveillance Report. Atlanta, GA: Centers for Disease Control and Prevention; 1999. [Google Scholar]
- 2.Estimates of Persons Living with AIDS in New York City. New York: Office of AIDS Surveillance, New York City Department of Health; 1999. [Google Scholar]
- 3.Chiasson MA, Berenson L, Li W, et al. Declining AIDS mortality in New York City. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;21:59–64. doi: 10.1097/00126334-199905010-00008. [DOI] [PubMed] [Google Scholar]
- 4.Spira R, Marimoutou C, Binquet C, et al. Rapid change in the use of antiretroviral agents and improvement in a population of HIV-infected patients: France, 1995–1997. Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA) J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:358–364. doi: 10.1097/00042560-199808010-00007. [DOI] [PubMed] [Google Scholar]
- 5.Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA. 1998;280:1497–1503. doi: 10.1001/jama.280.17.1497. [DOI] [PubMed] [Google Scholar]
- 6.Cascade Collaboration Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet. 2000;355:1158–1159. [PubMed] [Google Scholar]
- 7.Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725–733. doi: 10.1056/NEJM199709113371101. [DOI] [PubMed] [Google Scholar]
- 8.Cameron B, Heath-Chiozzi M, Danner S, et al. Randomized placebo—controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study. Lancet. 1998;351(9102):543–549. doi: 10.1016/S0140-6736(97)04161-5. [DOI] [PubMed] [Google Scholar]
- 9.NCHS Instruction Manual: Part 2a. Hyattsville, MD: Public Health Service; 1995. Vital statistics, instructions for classifying the underlying cause of death; pp. 17–42. [Google Scholar]
- 10.Murphy R, El-Sadr W, Cheung T, et al. Impact of protease inhibitor containing regimens on the risk of developing opportunistic infections and mortality in the CPCRA 034/ACTG 277 Study. Paper presented at:Fifth Conference on Retroviruses and Opportunistic Injections; February 1–5, 1998; Chicago. Abstract 18.
- 11.Moore RD, Chiasson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS. 1999;13:1933–1942. doi: 10.1097/00002030-199910010-00017. [DOI] [PubMed] [Google Scholar]
- 12.Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ. 1997;315:1194–1199. doi: 10.1136/bmj.315.7117.1194. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860. doi: 10.1056/NEJM199803263381301. [DOI] [PubMed] [Google Scholar]
- 14.Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet. 1998;352(9142):1725–1730. doi: 10.1016/S0140-6736(98)03201-2. [DOI] [PubMed] [Google Scholar]
- 15.McNaghten AD, Hanson DL, Jones JL, Ward JW, Dworkin MS. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group. AIDS. 1999;13:1687–1695. doi: 10.1097/00002030-199909100-00012. [DOI] [PubMed] [Google Scholar]
- 16.Stein MD, Piette J, Mor V, et al. Differences in access to zidovudine (AZT) among symptomatic HIV-infected persons. J Gen Intern Med. 1991;6:35–40. doi: 10.1007/BF02599388. [DOI] [PubMed] [Google Scholar]
- 17.Hellinger FJ. The use of health services by women with HIV infection. Health Serv Res. 1993;28:543–561. [PMC free article] [PubMed] [Google Scholar]
- 18.Moore RD, Stanton D, Gopalan R, Chiasson RE. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med. 1994;330:763–768. doi: 10.1056/NEJM199403173301107. [DOI] [PubMed] [Google Scholar]
- 19.Piette JD, Mor V, Mayer K, Zierler S, Wachtel T. The effects of immune status and race on health service use among people with HIV disease. Am J Public Health. 1993;83:510–514. doi: 10.2105/ajph.83.4.510. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Hogg RS, Yip B, Kully C, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ. 1999;160:659–665. [PMC free article] [PubMed] [Google Scholar]
- 21.Pezzotti P, Napoli PA, Acciai S, et al. Increasing survival time after AIDS in Italy: the role of new combination antiretroviral therapies. Tuscany AIDS Study Group. AIDS. 1999;13(2):249–255. doi: 10.1097/00002030-199902040-00013. [DOI] [PubMed] [Google Scholar]
- 22.Chiasson MA, Heffess J, Li W, Singh T. Differential decline in AIDS mortality by gender and race/ethnicity in New York City. Paper presented at:National HIV Prevention Conference; August 29–September 1, 1999; Atlanta, GA. Abstract 550.